

Table 14.2.2.1.1.2
Summary of Neutralizing Antibody Titers
Per-Protocol Set for SARS-CoV-2-specific nAb from All Lots

Antibody: MN Endpoint Titer PARAMCD = MNET

Timepoint Data Category Statistic	Overall			
	mRNA-1273			
	N where ADSL.PPNABFL=Y and TRT01PN in (1, 2, 3)			
	Placebo (N=XXX)	50 µg (N=XXX)	100 µg (N=XXX)	Total (N=XXX)
	ADSL.TRT01P=1	ADSL.TRT01P=2	ADSL.TRT01P=3	
Baseline				
n[1]	xxx	xxx	xxx	xxx
GMT	xx.x	xx.x	xx.x	xx.x
95% CI [2]	xx.x, xx.x	xx.x, xx.x	xx.x, xx.x	xx.x, xx.x
Median	xx.x	xx.x	xx.x	xx.x
Min, Max	xx, xx	xx, xx	xx, xx	xx, xx
Baseline Summary of ADIS.AVAL where ADIS.PPNA2RFL=Y and ADIS.ABLFL=Y and ADIS.ANL01FL=Y and PARAMCD = MNET				

Notes are listed on last page.

Program: \Moderna MODMRNA1273P201\Part A end of Part A\TLF\t140202010102.sas 11JUL2021 15:15 Database Lock Date: 10JUN2021

Table 14.2.2.1.1.2
Summary of Neutralizing Antibody Titers
Per-Protocol Set for SARS-CoV-2-specific nAb from All Lots

Antibody: MN Endpoint Titer

Timepoint Data Category Statistic	Overall			
	Placebo (N=XXX)	50 µg (N=XXX)	100 µg (N=XXX)	Total (N=XXX)
Day 29	mRNA-1273			
n[3]	xxx			
GMT	xx.x			
95% CI [2]	xx.x, xx.x			
Median	xx.x			
Min, Max	xx, xxx			
GMFR	x.xx			
95% CI [2]	x.xx, x.xx			
Seroconversion [4]				
n[5] (%)	xxx (xx.x)			
95% CI [6]	xx.x, xx.x			
>=2-fold Increase from Baseline [7]				
n[5] (%)	xxx (xx.x)			
95% CI [6]	xx.x, xx.x			
>=3-fold Increase from Baseline [7]				
n[5] (%)	xxx (xx.x)			
95% CI [6]	xx.x, xx.x			
>=4-fold Increase from Baseline [7]				
n[5] (%)	xxx (xx.x)			
95% CI [6]	xx.x, xx.x			

Notes are listed on last page.

Program: \Moderna MODMRNA1273P201\Part A end of Part A\TLF\t140202010102.sas 11JUL2021 15:15 Database Lock Date: 10JUN2021